Go Pro

Healthcare and Medical Stocks List

This page shows information about the 50 largest healthcare and medical sector stocks including Eli Lilly and Company, Johnson & Johnson, AbbVie and UnitedHealth Group.

Eli Lilly and Company stock logo

1. Eli Lilly and Company NYSE:LLY

$1,215.41 -0.42 (-0.03%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$1,224.00 +8.59 (+0.71%)
As of 04:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. More about Eli Lilly and Company

Pros of Eli Lilly and Company

  • The company recently reported earnings per share significantly above analysts' expectations, indicating strong financial performance and potential for future growth.
  • Eli Lilly and Co's revenue for the latest quarter showed a remarkable year-over-year increase, suggesting robust demand for its products and effective business strategies.
  • The current stock price is around $720, reflecting investor confidence and market interest in the company's future prospects.

Cons of Eli Lilly and Company

  • The company's payout ratio is relatively low, which may indicate that it is retaining a significant portion of its earnings for reinvestment rather than returning it to shareholders.
  • While recent performance has been strong, there is always the risk of market volatility affecting stock prices, which could impact investor returns.
  • Institutional investors hold a large percentage of the company's stock, which can lead to less control for individual investors and potential volatility if large shareholders decide to sell.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$1.14 trillion
P/E Ratio
43.18
Consensus Rating
Moderate Buy
Consensus Price Target
$1,260.33 (+3.7% Upside)
Volume
2.09 million shares
Average Volume
2.93 million shares
Today's Range
$1,200.37
$1,230.00
50-Day Range
$851.65
$1,233.32
52-Week Range
$623.78
$1,249.45
Dividend Yield
0.57%
Johnson & Johnson stock logo

2. Johnson & Johnson NYSE:JNJ

$258.48 -4.92 (-1.87%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$260.20 +1.72 (+0.67%)
As of 04:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. More about Johnson & Johnson

Pros of Johnson & Johnson

  • The stock has received multiple "buy" ratings from reputable analysts, indicating strong confidence in its future performance.
  • Recent price targets from analysts suggest a potential upside, with estimates ranging from $263.00 to $275.00, which could lead to significant returns for investors.
  • The current stock price is around $241, which may present a buying opportunity for investors looking for value in a well-established company.

Cons of Johnson & Johnson

  • Insider selling activity, such as the recent sale of 10,000 shares by an executive vice president, may raise concerns about the company's future prospects.
  • Despite positive ratings, the stock has seen fluctuations, and the current price may not reflect its long-term growth potential.
  • Corporate insiders own only a small percentage (0.16%) of the company's stock, which could indicate a lack of confidence in the company's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$634.06 billion
P/E Ratio
29.88
Consensus Rating
Moderate Buy
Consensus Price Target
$257.74 (-0.3% Downside)
Volume
6.38 million shares
Average Volume
8.30 million shares
Today's Range
$258.13
$263.45
50-Day Range
$221.17
$267.35
52-Week Range
$154.80
$269.43
Dividend Yield
2.03%
AbbVie stock logo

3. AbbVie NYSE:ABBV

$249.98 -2.76 (-1.09%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$250.75 +0.77 (+0.31%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. More about AbbVie

Pros of AbbVie

  • AbbVie recently reported earnings per share (EPS) of $2.65, exceeding analysts' expectations, indicating strong financial performance and potential for growth.
  • The company achieved a revenue of $15 billion for the quarter, surpassing estimates, which reflects robust demand for its products and a positive outlook for future sales.
  • AbbVie has a promising pipeline, including the recent FDA approval of Skyrizi for pediatric use, expanding its market reach and potential revenue streams.

Cons of AbbVie

  • AbbVie has a notably high dividend payout ratio of 340.89%, which may raise concerns about sustainability and the ability to maintain dividends in the long term.
  • The company reported a negative return on equity of 576.45%, indicating potential inefficiencies in generating profit from shareholders' equity.
  • Despite recent successes, AbbVie faces significant competition in the biopharmaceutical market, which could impact its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$446.54 billion
P/E Ratio
123.14
Consensus Rating
Moderate Buy
Consensus Price Target
$258.19 (+3.3% Upside)
Volume
5.52 million shares
Average Volume
8.90 million shares
Today's Range
$247.99
$254.86
50-Day Range
$201.24
$260.88
52-Week Range
$184.63
$261.64
Dividend Yield
2.74%
UnitedHealth Group stock logo

4. UnitedHealth Group NYSE:UNH

$430.88 +5.28 (+1.24%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$431.94 +1.06 (+0.25%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. More about UnitedHealth Group

Pros of UnitedHealth Group

  • The company recently reported earnings per share (EPS) of $7.23, exceeding analyst expectations, which indicates strong financial performance and effective management.
  • UnitedHealth Group has demonstrated consistent revenue growth, with a year-over-year increase of 2.0%, suggesting resilience in its business model.
  • The current stock price is around $500, reflecting a stable investment opportunity in the healthcare sector.

Cons of UnitedHealth Group

  • The payout ratio is currently at 70.09%, which indicates that a significant portion of earnings is being distributed as dividends, potentially limiting funds available for reinvestment in growth opportunities.
  • Despite recent revenue growth, the net margin stands at 2.68%, which may raise concerns about profitability in a competitive healthcare market.
  • Analysts have set a slightly lower EPS estimate of 18.32 for the current year compared to the company's guidance of 18.250, which could indicate potential challenges in meeting growth expectations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$386.51 billion
P/E Ratio
32.54
Consensus Rating
Moderate Buy
Consensus Price Target
$417.38 (-3.1% Downside)
Volume
5.56 million shares
Average Volume
5.67 million shares
Today's Range
$423.52
$434.30
50-Day Range
$363.83
$430.88
52-Week Range
$234.60
$434.30
Dividend Yield
2.18%
Merck & Co., Inc. stock logo

5. Merck & Co., Inc. NYSE:MRK

$125.17 -0.82 (-0.65%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$124.99 -0.18 (-0.15%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. More about Merck & Co., Inc.

Pros of Merck & Co., Inc.

  • Merck has demonstrated strong financial performance with a return on equity of over 27%, indicating effective management and profitability.
  • The company recently reported quarterly revenue exceeding expectations, showcasing its ability to generate sales growth in a competitive market.
  • Merck's annualized dividend yield is approximately 2.6%, providing a steady income stream for investors through its quarterly dividend payments.

Cons of Merck & Co., Inc.

  • Merck's dividend payout ratio is quite high at nearly 96%, which may raise concerns about the sustainability of its dividend payments in the long term.
  • The biopharmaceutical industry is highly competitive, and Merck faces significant pressure from other companies developing similar therapies and vaccines.
  • Market volatility can impact stock prices, and recent fluctuations may pose risks for investors looking for stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$311.17 billion
P/E Ratio
35.26
Consensus Rating
Moderate Buy
Consensus Price Target
$132.72 (+6.0% Upside)
Volume
6.97 million shares
Average Volume
11.11 million shares
Today's Range
$124.45
$128.07
50-Day Range
$109.33
$129.34
52-Week Range
$76.66
$130.29
Dividend Yield
2.70%
Novartis stock logo

6. Novartis NYSE:NVS

$154.70 -0.47 (-0.30%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$155.20 +0.50 (+0.32%)
As of 04:36 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. More about Novartis

Pros of Novartis

  • Novartis AG is actively engaged in the development of innovative therapies, including inclisiran, which targets LDL cholesterol reduction, showcasing its commitment to addressing significant health issues.
  • The current stock price is around $126.40, which may present a favorable entry point for investors looking to capitalize on potential growth in the pharmaceutical sector.
  • With a strong focus on various therapeutic areas such as oncology and immunology, Novartis AG is well-positioned to benefit from increasing demand for advanced healthcare solutions.

Cons of Novartis

  • The short percentage of float is relatively low, suggesting that there may not be significant bearish sentiment among investors, which could limit potential upside.
  • Despite recent performance, the pharmaceutical industry faces regulatory challenges that could impact Novartis AG's ability to bring new products to market efficiently.
  • Institutional ownership is at 7.05%, which may indicate a lack of strong institutional backing compared to competitors, potentially affecting stock stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$296.09 billion
P/E Ratio
22.16
Consensus Rating
Hold
Consensus Price Target
$141.20 (-8.7% Downside)
Volume
2.27 million shares
Average Volume
2.04 million shares
Today's Range
$153.79
$155.47
50-Day Range
$142.99
$159.82
52-Week Range
$112.34
$170.46
Dividend Yield
1.99%
Novo Nordisk A/S stock logo

7. Novo Nordisk A/S NYSE:NVO

$48.93 +0.04 (+0.09%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$49.00 +0.07 (+0.14%)
As of 04:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. More about Novo Nordisk A/S

Pros of Novo Nordisk A/S

  • The current stock price is around $43.90, which may present a buying opportunity for investors looking for growth in the pharmaceutical sector.
  • With a strong return on equity of over 63%, Novo Nordisk demonstrates effective management and profitability, indicating potential for continued financial success.
  • The company reported impressive quarterly earnings of $1.03 per share, showcasing its ability to generate substantial profits.

Cons of Novo Nordisk A/S

  • Recent downgrades from several analysts, including a shift from "buy" to "hold," may indicate concerns about the stock's future performance.
  • The price-to-earnings ratio is around 10.77, which, while not excessively high, may suggest that the stock is not undervalued compared to its peers.
  • Market volatility, as indicated by a beta of 0.78, suggests that the stock may not be as stable as some investors prefer, potentially leading to fluctuations in investment value.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$218.29 billion
P/E Ratio
11.49
Consensus Rating
Hold
Consensus Price Target
$65.56 (+34.0% Upside)
Volume
5.41 million shares
Average Volume
11.06 million shares
Today's Range
$48.58
$49.38
50-Day Range
$40.28
$50.39
52-Week Range
$35.12
$71.79
Dividend Yield
3.57%
Amgen stock logo

8. Amgen NASDAQ:AMGN

$363.62 -4.37 (-1.19%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$365.38 +1.76 (+0.48%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. More about Amgen

Pros of Amgen

  • Amgen Inc. reported strong earnings per share (EPS) of $5.15 for the latest quarter, surpassing analysts' expectations, which indicates robust financial performance and effective management.
  • The company has a high return on equity of 137.41%, suggesting that it is highly efficient in generating profits from shareholders' equity, which can be attractive to investors looking for strong returns.
  • Amgen Inc. achieved a revenue of $8.62 billion for the quarter, slightly above analyst estimates, reflecting solid demand for its products and a 5.8% increase year-over-year, indicating growth potential.

Cons of Amgen

  • Despite strong earnings, the stock has seen insider selling, with a senior vice president recently selling 1,237 shares, which could raise concerns about the company's future prospects from those within the organization.
  • Amgen Inc. has a relatively low insider ownership of 0.85%, which may suggest a lack of alignment between management and shareholders, potentially impacting investor confidence.
  • The biotechnology sector can be highly volatile and subject to regulatory changes, which may pose risks to Amgen Inc.'s business operations and stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$198.61 billion
P/E Ratio
25.30
Consensus Rating
Hold
Consensus Price Target
$355.73 (-2.2% Downside)
Volume
1.72 million shares
Average Volume
2.81 million shares
Today's Range
$361.03
$368.75
50-Day Range
$324.39
$374.15
52-Week Range
$269.77
$391.29
Dividend Yield
2.74%
Thermo Fisher Scientific stock logo

9. Thermo Fisher Scientific NYSE:TMO

$523.58 +13.45 (+2.64%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$525.00 +1.42 (+0.27%)
As of 04:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. More about Thermo Fisher Scientific

Pros of Thermo Fisher Scientific

  • The current stock price is around $643, reflecting strong market performance and investor confidence in the company's growth potential.
  • Thermo Fisher Scientific Inc. reported a significant increase in quarterly revenue, demonstrating a year-over-year growth of 6.2%, which indicates robust demand for its products and services.
  • The company has a solid return on equity of 16.86%, suggesting effective management and a strong ability to generate profits from shareholders' investments.

Cons of Thermo Fisher Scientific

  • The price-to-earnings ratio of 27.77 may suggest that the stock is overvalued compared to its earnings, which could deter value-focused investors.
  • The price-to-earnings-growth ratio of 2.27 indicates that the stock's price may be high relative to its expected earnings growth, which could limit upside potential.
  • With a beta of 0.88, the stock is less volatile than the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$189.58 billion
P/E Ratio
28.78
Consensus Rating
Moderate Buy
Consensus Price Target
$601.61 (+14.9% Upside)
Volume
1.37 million shares
Average Volume
2.01 million shares
Today's Range
$506.98
$524.85
50-Day Range
$438.16
$523.58
52-Week Range
$403.36
$643.99
Dividend Yield
0.37%
Gilead Sciences stock logo

10. Gilead Sciences NASDAQ:GILD

$134.84 -0.98 (-0.72%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$135.36 +0.52 (+0.38%)
As of 04:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. More about Gilead Sciences

Pros of Gilead Sciences

  • The company recently reported earnings per share of $2.03, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Gilead Sciences, Inc. has a solid market capitalization of approximately $155.43 billion, suggesting it is a well-established player in the biopharmaceutical industry.
  • The firm has a healthy return on equity of 48.19%, reflecting effective management and the ability to generate profits from shareholders' equity.

Cons of Gilead Sciences

  • The company has set its fiscal year 2026 guidance at a range of -1.050 to -0.650 EPS, indicating potential challenges ahead in maintaining profitability.
  • Analysts predict a negative earnings per share of -0.8 for the current fiscal year, which could signal underlying issues affecting the company's financial health.
  • Gilead Sciences, Inc. has a debt-to-equity ratio of 0.89, which, while manageable, suggests that the company is utilizing a significant amount of debt to finance its operations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$168.63 billion
P/E Ratio
18.37
Consensus Rating
Moderate Buy
Consensus Price Target
$159.04 (+17.9% Upside)
Volume
5.84 million shares
Average Volume
8.03 million shares
Today's Range
$133.27
$136.06
50-Day Range
$121.48
$136.36
52-Week Range
$107.75
$157.29
Dividend Yield
2.41%
Abbott Laboratories stock logo

11. Abbott Laboratories NYSE:ABT

$94.25 -0.93 (-0.98%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$94.73 +0.48 (+0.51%)
As of 04:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More about Abbott Laboratories

Pros of Abbott Laboratories

  • The current stock price is around $100, reflecting a stable position in the market.
  • Abbott Laboratories has a strong dividend payout ratio of 70.59%, indicating a commitment to returning value to shareholders through regular dividends.
  • The company has set ambitious earnings per share (EPS) guidance for FY 2026, projecting between 5.380 and 5.580, which suggests potential growth in profitability.

Cons of Abbott Laboratories

  • Despite a solid dividend, the high payout ratio may limit Abbott's ability to reinvest in growth opportunities, which could affect long-term performance.
  • Market volatility and economic uncertainties could impact Abbott's sales, particularly in its established pharmaceuticals segment.
  • Competition in the healthcare sector is intense, and Abbott may face challenges in maintaining its market share against emerging players.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$165.79 billion
P/E Ratio
26.40
Consensus Rating
Moderate Buy
Consensus Price Target
$118.42 (+25.6% Upside)
Volume
8.30 million shares
Average Volume
12.91 million shares
Today's Range
$93.91
$94.98
50-Day Range
$82.58
$95.80
52-Week Range
$81.97
$137.49
Dividend Yield
2.65%
Intuitive Surgical stock logo

12. Intuitive Surgical NASDAQ:ISRG

$411.55 -3.55 (-0.86%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$413.50 +1.94 (+0.47%)
As of 04:31 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. More about Intuitive Surgical

Pros of Intuitive Surgical

  • The company reported strong earnings per share of $2.50 for the latest quarter, significantly exceeding analyst expectations, which indicates robust financial performance.
  • Intuitive Surgical, Inc. has shown impressive revenue growth, with a 23% increase compared to the same quarter last year, suggesting a strong demand for its products.
  • The current stock price is around $420, reflecting a solid position in the market and potential for future appreciation as the company continues to innovate.

Cons of Intuitive Surgical

  • Recent insider selling, including significant transactions by senior executives, may raise concerns about the company's future prospects and could indicate a lack of confidence among insiders.
  • Some analysts have lowered their price targets for the stock, which could suggest a more cautious outlook on the company's growth potential in the near term.
  • The stock has experienced fluctuations, and while it has shown growth, market volatility could pose risks for investors looking for stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$147.01 billion
P/E Ratio
49.88
Consensus Rating
Moderate Buy
Consensus Price Target
$569.20 (+38.3% Upside)
Volume
1.95 million shares
Average Volume
2.32 million shares
Today's Range
$409.00
$416.25
50-Day Range
$397.68
$457.61
52-Week Range
$396.68
$603.88
Dividend Yield
N/A
Pfizer stock logo

13. Pfizer NYSE:PFE

$24.22 +0.17 (+0.69%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$24.28 +0.06 (+0.24%)
As of 04:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. More about Pfizer

Pros of Pfizer

  • The company recently reported earnings per share (EPS) of $0.75, exceeding analyst expectations, which indicates strong financial performance and potential for growth.
  • Pfizer Inc. has a solid revenue stream, with quarterly revenue reaching approximately $14.45 billion, surpassing estimates and showing a year-over-year increase of 5.4%.
  • The current stock price is around $28.82, which reflects a stable valuation in the biopharmaceutical sector, making it an attractive option for investors.

Cons of Pfizer

  • The dividend payout ratio is notably high at 131.30%, which may raise concerns about the sustainability of dividend payments in the long term.
  • Pfizer Inc. experienced a decline in EPS compared to the same quarter last year, where it was $0.92, indicating potential challenges in maintaining profitability.
  • Analysts have mixed ratings on the stock, with a significant number issuing "Hold" ratings, suggesting uncertainty about future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$137.07 billion
P/E Ratio
18.49
Consensus Rating
Hold
Consensus Price Target
$28.56 (+17.9% Upside)
Volume
29.15 million shares
Average Volume
48.54 million shares
Today's Range
$24.01
$24.30
50-Day Range
$23.64
$26.75
52-Week Range
$23.11
$28.75
Dividend Yield
7.15%
Danaher stock logo

14. Danaher NYSE:DHR

$195.75 +4.98 (+2.61%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$195.96 +0.21 (+0.11%)
As of 04:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. More about Danaher

Pros of Danaher

  • The current stock price is around $188, which reflects a strong market position and potential for growth.
  • Danaher Co. has demonstrated solid financial health with a quick ratio of 1.52 and a current ratio of 1.87, indicating good short-term liquidity and ability to cover liabilities.
  • The company reported a net margin of 14.89%, showcasing effective cost management and profitability.

Cons of Danaher

  • The company has a price-to-earnings (P/E) ratio of 34.81, which may indicate that the stock is overvalued compared to its earnings.
  • Recent revenue of $5.95 billion fell short of analysts' expectations of $6 billion, which could raise concerns about future growth potential.
  • Danaher Co. has a beta of 0.81, suggesting lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$135.02 billion
P/E Ratio
37.86
Consensus Rating
Moderate Buy
Consensus Price Target
$233.52 (+19.3% Upside)
Volume
2.64 million shares
Average Volume
3.75 million shares
Today's Range
$190.00
$195.99
50-Day Range
$161.95
$197.85
52-Week Range
$160.93
$242.80
Dividend Yield
0.84%
CVS Health stock logo

15. CVS Health NYSE:CVS

$102.69 -1.78 (-1.70%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$102.92 +0.23 (+0.22%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. More about CVS Health

Pros of CVS Health

  • The current stock price is around $93, which reflects a strong performance compared to its one-year low of $58.50 and high of $106.15, indicating potential for growth.
  • CVS Health Co. reported impressive quarterly earnings, with earnings per share (EPS) of $2.57, surpassing analysts' expectations, which demonstrates strong operational performance.
  • The company has shown a year-over-year revenue increase of 6.2%, indicating a solid growth trajectory and resilience in its business model.

Cons of CVS Health

  • The company has a relatively high P/E ratio of around 46.18, which may indicate that the stock is overvalued compared to its earnings, potentially leading to a price correction.
  • CVS Health Co. has a net margin of only 0.72%, suggesting that profitability is limited, which could impact long-term financial health.
  • The quick ratio of 0.66 and current ratio of 0.87 indicate potential liquidity issues, meaning the company may struggle to meet short-term obligations.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$133.30 billion
P/E Ratio
45.24
Consensus Rating
Moderate Buy
Consensus Price Target
$102.84 (+0.1% Upside)
Volume
8.47 million shares
Average Volume
7.38 million shares
Today's Range
$102.34
$105.15
50-Day Range
$80.67
$104.83
52-Week Range
$58.50
$106.15
Dividend Yield
2.55%
Vertex Pharmaceuticals stock logo

16. Vertex Pharmaceuticals NASDAQ:VRTX

$496.50 -1.93 (-0.39%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$493.52 -2.98 (-0.60%)
As of 04:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More about Vertex Pharmaceuticals

Pros of Vertex Pharmaceuticals

  • Vertex Pharmaceuticals Incorporated has received multiple "buy" ratings from analysts, indicating strong confidence in the company's future performance.
  • The current stock price is around $440, which is significantly lower than its 12-month high, suggesting potential for growth as the market recovers.
  • The company reported a net margin of over 35%, showcasing its ability to generate profit efficiently, which is attractive for investors looking for financially healthy companies.

Cons of Vertex Pharmaceuticals

  • Despite its strong performance, Vertex Pharmaceuticals Incorporated's stock has seen fluctuations, with a 12-month low of $362.50, which may raise concerns about volatility.
  • Insider selling has occurred, with executives selling shares recently, which could signal a lack of confidence in the stock's short-term performance.
  • The company's price-to-earnings (P/E) ratio is 28.19, which may be considered high, suggesting that the stock could be overvalued compared to its earnings.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$126.50 billion
P/E Ratio
29.45
Consensus Rating
Moderate Buy
Consensus Price Target
$557.09 (+12.2% Upside)
Volume
2.09 million shares
Average Volume
1.89 million shares
Today's Range
$482.11
$500.77
50-Day Range
$423.24
$529.59
52-Week Range
$362.50
$533.67
Dividend Yield
N/A
Stryker stock logo

17. Stryker NYSE:SYK

$326.87 +0.02 (+0.01%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$327.06 +0.19 (+0.06%)
As of 04:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. More about Stryker

Pros of Stryker

  • The company has set its FY 2026 earnings per share (EPS) guidance between 14.900 and 15.100, indicating strong growth potential.
  • Recent quarterly revenue showed an increase of 2.6% compared to the same period last year, suggesting a positive trend in sales performance.
  • The current stock price is around $306, which may present a buying opportunity for investors looking for growth in the medical technology sector.

Cons of Stryker

  • Insider selling has been significant, with a total of 323,264 shares sold recently, which may indicate a lack of confidence among executives in the company's short-term performance.
  • The stock is currently owned 4.60% by insiders, which may suggest limited insider confidence in the company's future growth prospects.
  • Despite the revenue growth, the overall market conditions in the medical technology sector can be volatile, which may impact Stryker Co.'s performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$125.30 billion
P/E Ratio
37.83
Consensus Rating
Moderate Buy
Consensus Price Target
$392.87 (+20.2% Upside)
Volume
1.94 million shares
Average Volume
2.48 million shares
Today's Range
$321.79
$330.22
50-Day Range
$282.85
$332.31
52-Week Range
$281.00
$404.87
Dividend Yield
1.08%
Bristol Myers Squibb stock logo

18. Bristol Myers Squibb NYSE:BMY

$57.89 +0.35 (+0.61%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$57.78 -0.11 (-0.20%)
As of 04:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More about Bristol Myers Squibb

Pros of Bristol Myers Squibb

  • The company reported a quarterly revenue of approximately $11.49 billion, exceeding analyst expectations, indicating strong financial performance.
  • Bristol-Myers Squibb has a high return on equity of about 64.87%, suggesting effective management and profitability in generating returns for shareholders.
  • The current stock price is around $61.67, which is near its 12-month high of $62.89, reflecting positive market sentiment.

Cons of Bristol Myers Squibb

  • The net margin stands at 15.01%, which, while positive, may indicate that there is room for improvement in cost management and profitability.
  • Insider ownership is relatively low at 0.05%, which could suggest a lack of confidence from executives in the company's future performance.
  • Recent insider selling, including a significant transaction by an executive vice president, may raise concerns about the company's short-term outlook.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$117.50 billion
P/E Ratio
16.26
Consensus Rating
Hold
Consensus Price Target
$61.31 (+5.9% Upside)
Volume
7.63 million shares
Average Volume
12.14 million shares
Today's Range
$57.14
$58.00
50-Day Range
$54.10
$60.75
52-Week Range
$42.52
$62.89
Dividend Yield
4.38%
GSK stock logo

19. GSK NYSE:GSK

$52.51 -0.01 (-0.01%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$52.72 +0.21 (+0.39%)
As of 04:37 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. More about GSK

Pros of GSK

  • The current stock price is around $43.16, which may present a buying opportunity for investors looking for value.
  • GSK plc has shown a positive fifty-two week performance, indicating potential growth and investor confidence.
  • Institutional ownership is relatively high, suggesting that large investors have confidence in GSK plc's future prospects.

Cons of GSK

  • Recent performance has shown a decline in the fifty-two week performance, which may raise concerns about the company's growth trajectory.
  • The average daily volume has decreased, indicating reduced trading activity and potentially lower liquidity for investors.
  • There has been a notable decrease in shares shorted compared to the previous month, which could suggest a lack of confidence among some investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$106.36 billion
P/E Ratio
13.65
Consensus Rating
Hold
Consensus Price Target
$53.00 (+0.9% Upside)
Volume
2.36 million shares
Average Volume
3.41 million shares
Today's Range
$52.30
$52.85
50-Day Range
$49.06
$53.69
52-Week Range
$35.45
$61.69
Dividend Yield
3.45%
Medtronic stock logo

20. Medtronic NYSE:MDT

$82.37 +0.36 (+0.44%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$82.58 +0.21 (+0.26%)
As of 04:25 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. More about Medtronic

Pros of Medtronic

  • Medtronic plc recently reported earnings per share of $1.55, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • The company achieved a revenue of $9.81 billion for the quarter, surpassing forecasts, showcasing its ability to generate significant sales and market demand for its products.
  • Medtronic plc has a solid return on equity of 14.51%, reflecting effective management and the ability to generate profits from shareholders' investments.

Cons of Medtronic

  • The company's earnings per share decreased from $1.62 in the same quarter last year, indicating a potential decline in profitability that could concern investors.
  • Medtronic plc's net margin of 13.20% may suggest that while the company is profitable, there could be pressures on its profitability compared to competitors.
  • The payout ratio is currently at 77.21%, which indicates that a significant portion of earnings is being distributed as dividends, potentially limiting funds available for reinvestment in growth opportunities.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$104.98 billion
P/E Ratio
22.08
Consensus Rating
Moderate Buy
Consensus Price Target
$98.96 (+20.1% Upside)
Volume
5.52 million shares
Average Volume
8.79 million shares
Today's Range
$81.10
$83.00
50-Day Range
$73.72
$83.77
52-Week Range
$73.31
$106.33
Dividend Yield
3.51%
Sanofi stock logo

21. Sanofi NASDAQ:SNY

$43.90 +1.12 (+2.62%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$43.78 -0.12 (-0.28%)
As of 04:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. More about Sanofi

Pros of Sanofi

  • The current stock price is around $43.60, which is near its one-year low, potentially offering a buying opportunity for value investors.
  • Sanofi has a strong market capitalization of over $106 billion, indicating a solid position in the pharmaceutical industry, which can provide stability and growth potential.
  • The company has a low debt-to-equity ratio of 0.20, suggesting that it is not heavily reliant on debt for financing, which can reduce financial risk for investors.

Cons of Sanofi

  • Despite a strong market presence, the stock has shown limited price movement, which may indicate a lack of growth momentum compared to other biotech firms.
  • The company's quick ratio of 0.73 suggests that it may face challenges in meeting short-term liabilities, which could raise concerns about liquidity.
  • Recent analyst ratings include several "neutral" assessments, which may reflect uncertainty about the company's growth prospects in the near term.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$103.72 billion
P/E Ratio
12.26
Consensus Rating
Hold
Consensus Price Target
$49.50 (+12.8% Upside)
Volume
4.11 million shares
Average Volume
3.98 million shares
Today's Range
$43.28
$44.11
50-Day Range
$41.33
$46.58
52-Week Range
$40.89
$52.68
Dividend Yield
4.13%
McKesson stock logo

22. McKesson NYSE:MCK

$793.32 -25.34 (-3.10%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$793.24 -0.08 (-0.01%)
As of 04:01 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. More about McKesson

Pros of McKesson

  • The current stock price is around $769, which is significantly lower than its 12-month high of $999, potentially offering a buying opportunity for investors looking for value.
  • McKesson Co. has a strong market capitalization of approximately $92.05 billion, indicating a solid position in the healthcare sector and the ability to invest in growth opportunities.
  • The company reported a year-over-year revenue increase of 6.0%, showcasing its ability to grow despite market challenges, which can be a positive indicator for future performance.

Cons of McKesson

  • The company has a negative return on equity of 345.35%, which may raise concerns about its profitability and efficiency in generating returns for shareholders.
  • McKesson Co. reported quarterly revenue that fell short of analysts' expectations, which could indicate potential challenges in meeting future growth targets.
  • The dividend yield is relatively low at 0.4%, which may not be attractive for income-focused investors looking for higher returns from dividends.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$95.85 billion
P/E Ratio
20.62
Consensus Rating
Moderate Buy
Consensus Price Target
$960.53 (+21.1% Upside)
Volume
1.01 million shares
Average Volume
1.11 million shares
Today's Range
$786.81
$817.80
50-Day Range
$724.87
$823.68
52-Week Range
$637.00
$999.00
Dividend Yield
0.40%
HCA Healthcare stock logo

23. HCA Healthcare NYSE:HCA

$408.77 -1.84 (-0.45%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$408.18 -0.59 (-0.15%)
As of 04:13 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. More about HCA Healthcare

Pros of HCA Healthcare

  • The company has shown a solid revenue growth of 4.3% year-over-year, indicating a positive trend in its business performance.
  • HCA Healthcare, Inc. has set its fiscal year 2026 earnings per share (EPS) guidance between 29.100 and 31.500, suggesting strong future profitability expectations.
  • The current stock price is around $412, which may present a buying opportunity for investors looking for growth in the healthcare sector.

Cons of HCA Healthcare

  • The company reported a negative return on equity of 295.93%, which may raise concerns about its efficiency in generating profits from shareholders' equity.
  • HCA Healthcare, Inc. missed analysts' consensus EPS estimates in its latest quarterly earnings report, which could indicate potential challenges in meeting future expectations.
  • With a price-to-earnings (P/E) ratio of 13.36, the stock may be considered overvalued compared to industry peers, which could deter value investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$91.09 billion
P/E Ratio
14.06
Consensus Rating
Moderate Buy
Consensus Price Target
$497.14 (+21.6% Upside)
Volume
1.04 million shares
Average Volume
1.40 million shares
Today's Range
$402.01
$412.46
50-Day Range
$360.99
$435.01
52-Week Range
$330.00
$556.52
Dividend Yield
0.76%
Elevance Health stock logo

24. Elevance Health NYSE:ELV

$419.89 +3.81 (+0.91%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$420.33 +0.44 (+0.11%)
As of 07/9/2026 06:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits. The company operates in the pharmacy services business; and markets and offers pharmacy services, including pharmacy benefit management, as well as home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services. In addition, it provides healthcare-related services and capabilities, including utilization management, behavioral health, integrated care delivery, palliative care, payment integrity services, subrogation services, and health and wellness programs, as well as services related to data management, information technology, and business operations. Further, the company is involved in the National Government Services business. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brand names. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Market Capitalization
$90.36 billion
P/E Ratio
17.86
Consensus Rating
Moderate Buy
Consensus Price Target
$425.95 (+1.4% Upside)
Volume
1.06 million shares
Average Volume
1.55 million shares
Today's Range
$415.76
$427.64
50-Day Range
$369.06
$424.16
52-Week Range
$273.71
$427.64
Dividend Yield
1.65%
Cigna Group stock logo

25. Cigna Group NYSE:CI

$291.32 +1.59 (+0.55%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$292.00 +0.68 (+0.23%)
As of 04:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. More about Cigna Group

Pros of Cigna Group

  • The current stock price is around $338.30, reflecting a consensus target price that suggests potential for growth.
  • The Cigna Group has a solid dividend yield of 2.2%, which can provide a steady income stream for investors.
  • With a dividend payout ratio of 26.45%, the company demonstrates a commitment to returning value to shareholders while maintaining sufficient reinvestment in the business.

Cons of Cigna Group

  • Some analysts have recently downgraded their price targets for The Cigna Group, which may indicate concerns about future performance.
  • The competitive landscape in the healthcare sector is intense, which could pressure profit margins and growth potential.
  • Market volatility can impact stock performance, and recent economic uncertainties may pose risks to The Cigna Group's financial stability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$76.64 billion
P/E Ratio
12.35
Consensus Rating
Moderate Buy
Consensus Price Target
$338.80 (+16.3% Upside)
Volume
1.20 million shares
Average Volume
1.48 million shares
Today's Range
$288.68
$296.60
50-Day Range
$271.03
$300.36
52-Week Range
$239.51
$315.47
Dividend Yield
2.15%
Regeneron Pharmaceuticals stock logo

26. Regeneron Pharmaceuticals NASDAQ:REGN

$667.95 +5.07 (+0.76%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$665.18 -2.77 (-0.41%)
As of 04:03 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. More about Regeneron Pharmaceuticals

Pros of Regeneron Pharmaceuticals

  • The company recently reported earnings per share of $9.47, exceeding analysts' expectations, which indicates strong financial performance and potential for future growth.
  • Regeneron Pharmaceuticals, Inc. has shown a significant year-over-year revenue increase of 19.0%, suggesting robust demand for its products and effective business strategies.
  • The current stock price is around $720, which may present a favorable entry point for investors looking to capitalize on the company's growth trajectory.

Cons of Regeneron Pharmaceuticals

  • The company's return on equity is 13.16%, which, while positive, may be lower compared to industry peers, indicating less efficiency in generating profits from shareholders' equity.
  • Regeneron Pharmaceuticals, Inc. has a relatively low dividend payout ratio of 9.16%, which may suggest that the company is retaining a significant portion of its earnings for reinvestment rather than returning it to shareholders.
  • Despite recent revenue growth, the biopharmaceutical sector can be volatile, and any setbacks in drug development or regulatory approvals could negatively impact the company's stock performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$70.08 billion
P/E Ratio
16.28
Consensus Rating
Moderate Buy
Consensus Price Target
$787.67 (+17.9% Upside)
Volume
671,997 shares
Average Volume
960,283 shares
Today's Range
$660.80
$669.16
50-Day Range
$600.66
$723.41
52-Week Range
$541.00
$821.11
Dividend Yield
0.56%
Boston Scientific stock logo

27. Boston Scientific NYSE:BSX

$44.96 +0.15 (+0.33%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$45.04 +0.09 (+0.19%)
As of 04:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. More about Boston Scientific

Pros of Boston Scientific

  • The current stock price is around $45, which may be seen as an attractive entry point for investors looking for potential growth.
  • Boston Scientific Co. has demonstrated strong financial performance, with a recent quarterly revenue increase of over 11% year-over-year, indicating robust demand for its medical equipment.
  • The company has initiated a significant stock buyback program, allowing for the repurchase of up to $5 billion in shares, which often signals that management believes the stock is undervalued and can enhance shareholder value.

Cons of Boston Scientific

  • The stock has experienced significant volatility, with a 52-week high of $109.50 and a low of $42.25, which may indicate uncertainty in the market.
  • Despite recent revenue growth, the company faces intense competition in the medical equipment sector, which could impact future profitability and market share.
  • The current price-to-earnings ratio is around 18.86, which may be considered high compared to industry averages, potentially signaling overvaluation.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$66.60 billion
P/E Ratio
18.81
Consensus Rating
Moderate Buy
Consensus Price Target
$81.32 (+80.9% Upside)
Volume
12.40 million shares
Average Volume
19.07 million shares
Today's Range
$44.10
$45.11
50-Day Range
$42.64
$57.71
52-Week Range
$42.25
$109.50
Dividend Yield
N/A
Cencora stock logo

28. Cencora NYSE:COR

$302.32 -7.26 (-2.34%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$302.42 +0.11 (+0.04%)
As of 07/9/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. More about Cencora

Pros of Cencora

  • The company has recently announced a share buyback plan allowing for the repurchase of $2.00 billion in shares, indicating management's belief that the stock is undervalued.
  • Cencora, Inc. reported a revenue increase of 3.9% compared to the same quarter last year, showcasing its growth potential in the healthcare services sector.
  • The current stock price is around $350, which reflects a favorable valuation compared to its historical performance and analyst price targets.

Cons of Cencora

  • The company reported earnings per share of $4.75, which missed analysts' expectations, indicating potential challenges in meeting growth targets.
  • Cencora's net margin is relatively low at 0.78%, which may raise concerns about profitability and operational efficiency.
  • Despite revenue growth, the company’s revenue of $78.36 billion fell short of consensus estimates, suggesting possible market pressures or operational hurdles.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$60.23 billion
P/E Ratio
23.18
Consensus Rating
Moderate Buy
Consensus Price Target
$367.75 (+21.6% Upside)
Volume
1.58 million shares
Average Volume
1.55 million shares
Today's Range
$299.82
$307.51
50-Day Range
$253.20
$311.42
52-Week Range
$244.82
$377.54
Dividend Yield
0.78%
argenex stock logo

29. argenex NASDAQ:ARGX

$909.49 -5.81 (-0.63%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$909.01 -0.48 (-0.05%)
As of 04:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. More about argenex

Pros of argenex

  • The current stock price is around $799, indicating a strong market position and potential for growth.
  • Recent short interest data shows a relatively low short percentage of float, suggesting that investors are not heavily betting against the stock.
  • With an average daily volume of approximately 345,000 shares, there is good liquidity, allowing investors to enter and exit positions more easily.

Cons of argenex

  • Institutional ownership is currently at 0%, which may indicate a lack of confidence from larger investors.
  • The company has a high number of shares shorted, which could lead to increased volatility if a short squeeze occurs.
  • Despite a stable stock price, the company has not shown significant performance over the past year, which may raise concerns about growth potential.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$56.92 billion
P/E Ratio
40.49
Consensus Rating
Moderate Buy
Consensus Price Target
$1,037.61 (+14.1% Upside)
Volume
287,236 shares
Average Volume
353,425 shares
Today's Range
$905.45
$925.31
50-Day Range
$776.02
$939.68
52-Week Range
$549.85
$953.58
Dividend Yield
N/A
Cardinal Health stock logo

30. Cardinal Health NYSE:CAH

$233.73 -3.42 (-1.44%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$233.40 -0.33 (-0.14%)
As of 04:29 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cardinal Health, Inc operates as a healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. More about Cardinal Health

Pros of Cardinal Health

  • The current stock price is around $246.93, which reflects a consensus target price indicating potential for growth.
  • Cardinal Health, Inc. has received multiple "outperform" ratings from analysts, suggesting strong confidence in its future performance.
  • The company has set its FY 2026 guidance at an EPS of 10.700-10.80, indicating expected profitability and growth in earnings.

Cons of Cardinal Health

  • Evercore recently decreased its price objective for Cardinal Health, Inc. from $260.00 to $240.00, indicating some analysts' concerns about future performance.
  • Despite a generally positive outlook, there are two analysts who have issued a Hold rating, suggesting caution among some investors.
  • The dividend yield of 0.9% may be considered low compared to other investment opportunities, potentially limiting income for dividend-focused investors.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$55.54 billion
P/E Ratio
35.74
Consensus Rating
Moderate Buy
Consensus Price Target
$249.13 (+6.6% Upside)
Volume
2.66 million shares
Average Volume
2.27 million shares
Today's Range
$231.83
$240.22
50-Day Range
$182.62
$239.36
52-Week Range
$137.75
$243.21
Dividend Yield
0.87%
Edwards Lifesciences stock logo

31. Edwards Lifesciences NYSE:EW

$91.32 -2.32 (-2.47%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$91.80 +0.48 (+0.52%)
As of 04:17 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. More about Edwards Lifesciences

Pros of Edwards Lifesciences

  • The company reported earnings per share of $0.78 for the latest quarter, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • Edwards Lifesciences Co. achieved a revenue of $1.65 billion during the quarter, reflecting a year-over-year increase of 16.7%, showcasing its ability to grow in a competitive market.
  • With a net margin of 17.39%, the company demonstrates effective cost management and profitability, which can lead to higher returns for investors.

Cons of Edwards Lifesciences

  • Despite strong earnings, the stock has seen insider selling, with significant shares sold recently, which could indicate a lack of confidence from those closest to the company.
  • While the company has a solid return on equity of 15.19%, it may not be as competitive compared to other firms in the medical technology sector, which could limit its attractiveness to investors.
  • Analysts have mixed ratings, with eight assigning a Hold rating, suggesting that some investors may be cautious about the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$53.92 billion
P/E Ratio
48.58
Consensus Rating
Moderate Buy
Consensus Price Target
$97.09 (+6.3% Upside)
Volume
5.55 million shares
Average Volume
4.33 million shares
Today's Range
$91.03
$93.22
50-Day Range
$77.11
$95.17
52-Week Range
$72.30
$96.29
Dividend Yield
N/A
Takeda Pharmaceutical stock logo

32. Takeda Pharmaceutical NYSE:TAK

$16.62 -0.13 (-0.75%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$16.61 -0.01 (-0.06%)
As of 07/9/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. More about Takeda Pharmaceutical

Pros of Takeda Pharmaceutical

  • The current stock price is around $13.73, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Takeda Pharmaceutical Company Limited has a diverse portfolio of products across various therapeutic areas, including oncology and immunology, which can help mitigate risks associated with reliance on a single product.
  • Recent collaborations and licensing agreements with notable companies and research institutions enhance Takeda's innovation potential and may lead to the development of new therapies, driving future growth.

Cons of Takeda Pharmaceutical

  • The institutional ownership percentage is relatively low at around 2.49%, which may indicate a lack of confidence from larger investors in the company's future performance.
  • Despite recent positive developments, the company's fifty-two week performance shows only a modest increase, suggesting that it may not be a high-growth investment at this time.
  • With a short percentage of float at approximately 0.26%, there may be concerns about market volatility and the potential for rapid price declines if investor sentiment shifts.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$53.31 billion
P/E Ratio
42.63
Consensus Rating
Hold
Consensus Price Target
N/A
Volume
2.39 million shares
Average Volume
2.48 million shares
Today's Range
$16.57
$16.69
50-Day Range
$15.02
$16.96
52-Week Range
$12.99
$18.90
Dividend Yield
2.87%
Humana stock logo

33. Humana NYSE:HUM

$397.80 +1.51 (+0.38%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$392.86 -4.94 (-1.24%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. More about Humana

Pros of Humana

  • The current stock price is around $263.86, which reflects a strong performance compared to its 52-week low of $163.11.
  • Humana Inc. reported a significant increase in revenue, with a year-over-year growth of 23.5%, indicating strong demand for its health insurance products.
  • The company has a solid dividend yield of approximately 1.0%, providing a steady income stream for investors.

Cons of Humana

  • The P/E/G ratio of 2.08 suggests that the stock may be overvalued relative to its growth rate, which could deter value-focused investors.
  • Humana Inc. experienced a decline in earnings per share (EPS) from $11.58 in the previous year to $10.31, indicating potential challenges in maintaining profitability.
  • The net margin of 0.82% is relatively low, which may raise concerns about the company's efficiency in converting revenue into profit.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$47.58 billion
P/E Ratio
42.55
Consensus Rating
Hold
Consensus Price Target
$303.74 (-23.6% Downside)
Volume
1.22 million shares
Average Volume
1.38 million shares
Today's Range
$390.97
$403.41
50-Day Range
$236.86
$409.92
52-Week Range
$163.11
$415.00
Dividend Yield
0.89%
IDEXX Laboratories stock logo

34. IDEXX Laboratories NASDAQ:IDXX

$558.60 +2.93 (+0.53%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$558.13 -0.47 (-0.08%)
As of 07/9/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. More about IDEXX Laboratories

Pros of IDEXX Laboratories

  • The current stock price is around $534, reflecting a strong market position and investor confidence in the company's growth potential.
  • IDEXX Laboratories, Inc. has a diverse product portfolio, including advanced point-of-care veterinary diagnostic products and water testing solutions, which cater to various markets and reduce dependency on a single revenue stream.
  • The company has demonstrated consistent growth, with a notable increase in its fifty-two week performance, indicating strong demand for its products and services.

Cons of IDEXX Laboratories

  • The company has experienced a slight month-to-month decrease in shares shorted, which may indicate some investor skepticism about its short-term performance.
  • With a relatively high number of shares shorted, there could be potential volatility in the stock price, which may deter risk-averse investors.
  • Despite strong performance, the competitive landscape in the health care equipment sector is intense, and new entrants could impact market share.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.83 billion
P/E Ratio
41.13
Consensus Rating
Moderate Buy
Consensus Price Target
$751.00 (+34.4% Upside)
Volume
807,093 shares
Average Volume
638,604 shares
Today's Range
$547.38
$562.02
50-Day Range
$526.44
$579.23
52-Week Range
$506.91
$769.98
Dividend Yield
N/A
Alnylam Pharmaceuticals stock logo

35. Alnylam Pharmaceuticals NASDAQ:ALNY

$312.79 -10.71 (-3.31%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$316.54 +3.76 (+1.20%)
As of 04:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. More about Alnylam Pharmaceuticals

Pros of Alnylam Pharmaceuticals

  • The company recently reported a significant increase in quarterly revenue, showcasing a year-over-year growth of nearly 100%, which indicates strong demand for its products.
  • Alnylam Pharmaceuticals, Inc. has a robust return on equity, suggesting effective management and profitability, which can be attractive to investors looking for solid financial performance.
  • The current stock price is around $295, which is relatively lower compared to its 1-year high, potentially offering a buying opportunity for investors looking for value.

Cons of Alnylam Pharmaceuticals

  • The stock has a high price-to-earnings ratio, which may suggest that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Insider selling activity has been noted, which could indicate a lack of confidence among executives regarding the company's future performance.
  • The company operates in a highly competitive biopharmaceutical market, which can pose risks to its market share and profitability.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$43.19 billion
P/E Ratio
85.46
Consensus Rating
Moderate Buy
Consensus Price Target
$461.39 (+47.5% Upside)
Volume
5.86 million shares
Average Volume
1.12 million shares
Today's Range
$311.10
$380.00
50-Day Range
$278.09
$323.50
52-Week Range
$273.11
$495.55
Dividend Yield
N/A
Haleon stock logo

36. Haleon NYSE:HLN

$9.72 -0.03 (-0.26%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$9.76 +0.04 (+0.41%)
As of 04:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. More about Haleon

Pros of Haleon

  • The current stock price is around $9.08, which may present a buying opportunity for investors looking for value in the consumer healthcare sector.
  • Haleon plc has a diverse product portfolio, including well-known brands in oral health, vitamins, and over-the-counter medications, which can help stabilize revenue streams.
  • The company has a long history, founded in 1715, which may instill confidence in its operational stability and experience in the market.

Cons of Haleon

  • There has been a notable decrease in shares shorted over the past month, indicating some investor skepticism about the stock's future performance.
  • The company has a short percentage of float that is relatively low, which may suggest limited investor confidence in significant price increases in the near term.
  • Institutional ownership is currently at 0%, which could indicate a lack of interest from larger, more experienced investors who often provide stability to a stock.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$42.98 billion
P/E Ratio
24.94
Consensus Rating
Moderate Buy
Consensus Price Target
N/A
Volume
8.42 million shares
Average Volume
9.14 million shares
Today's Range
$9.67
$9.74
50-Day Range
$8.71
$9.83
52-Week Range
$8.65
$11.28
Dividend Yield
2.59%
Becton, Dickinson and Company stock logo

37. Becton, Dickinson and Company NYSE:BDX

$150.70 +0.14 (+0.09%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$149.35 -1.35 (-0.89%)
As of 04:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. More about Becton, Dickinson and Company

Pros of Becton, Dickinson and Company

  • The current stock price is around $147.91, which is significantly lower than its 12-month high of $187.35, potentially offering a buying opportunity for investors looking for value.
  • Becton, Dickinson and Company reported a quarterly revenue increase of 5.2% compared to the same quarter last year, indicating strong growth and demand for its medical products.
  • The company has a solid return on equity of 15.37%, suggesting effective management and profitability, which can be attractive to investors seeking reliable returns.

Cons of Becton, Dickinson and Company

  • The company has a high dividend payout ratio of 106.33%, which may raise concerns about sustainability, as it indicates that the company is paying out more in dividends than it is earning.
  • Analysts have mixed ratings on the stock, with a consensus rating of "Hold," suggesting that there may be uncertainty about the stock's future performance.
  • Recent analyst downgrades, including a reduction from a "hold" to a "sell" rating, may indicate potential challenges ahead for the company.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$41.49 billion
P/E Ratio
38.15
Consensus Rating
Hold
Consensus Price Target
$180.29 (+19.6% Upside)
Volume
1.78 million shares
Average Volume
2.69 million shares
Today's Range
$148.23
$151.72
50-Day Range
$140.37
$158.10
52-Week Range
$127.59
$187.35
Dividend Yield
2.79%
Revolution Medicines stock logo

38. Revolution Medicines NASDAQ:RVMD

$191.13 +1.36 (+0.72%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$193.06 +1.94 (+1.01%)
As of 04:12 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Market Capitalization
$40.34 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$144.00 (-24.7% Downside)
Volume
1.61 million shares
Average Volume
3.06 million shares
Today's Range
$190.04
$193.83
50-Day Range
$140.55
$192.62
52-Week Range
$34.00
$193.83
Dividend Yield
N/A
Natera stock logo

39. Natera NASDAQ:NTRA

$281.85 +7.46 (+2.72%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$282.05 +0.20 (+0.07%)
As of 04:35 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.

Market Capitalization
$39.30 billion
P/E Ratio
N/A
Consensus Rating
Moderate Buy
Consensus Price Target
$265.33 (-5.9% Downside)
Volume
1.64 million shares
Average Volume
1.58 million shares
Today's Range
$273.00
$283.77
50-Day Range
$186.36
$283.80
52-Week Range
$131.81
$288.04
Dividend Yield
N/A
Teva Pharmaceutical Industries stock logo

40. Teva Pharmaceutical Industries NYSE:TEVA

$33.08 -0.16 (-0.47%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$32.87 -0.21 (-0.64%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Market Capitalization
$38.22 billion
P/E Ratio
24.88
Consensus Rating
Moderate Buy
Consensus Price Target
$41.78 (+26.3% Upside)
Volume
5.11 million shares
Average Volume
5.33 million shares
Today's Range
$32.41
$33.14
50-Day Range
$31.50
$36.36
52-Week Range
$14.99
$37.35
Dividend Yield
N/A
Agilent Technologies stock logo

41. Agilent Technologies NYSE:A

$133.56 +4.49 (+3.48%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$134.04 +0.48 (+0.36%)
As of 04:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. More about Agilent Technologies

Pros of Agilent Technologies

  • Agilent Technologies, Inc. has demonstrated strong financial performance with a return on equity of over 24%, indicating effective management and profitability relative to shareholder equity.
  • The company recently reported quarterly revenue exceeding expectations, showcasing a growth of 10% compared to the same quarter last year, which reflects its robust market position.
  • Agilent Technologies, Inc. has set an optimistic FY 2026 earnings per share (EPS) guidance of 6.000-6.100, suggesting potential for continued profitability and growth.

Cons of Agilent Technologies

  • Despite strong revenue growth, the company operates in a highly competitive market, which could pressure margins and limit future growth potential.
  • The dividend yield, while positive, is relatively low compared to other investment opportunities, which may not attract income-focused investors.
  • Agilent Technologies, Inc. has a significant reliance on the life sciences and diagnostics sectors, making it vulnerable to sector-specific downturns or regulatory changes.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$36.45 billion
P/E Ratio
26.82
Consensus Rating
Moderate Buy
Consensus Price Target
$159.35 (+19.3% Upside)
Volume
2.37 million shares
Average Volume
2.12 million shares
Today's Range
$127.87
$133.74
50-Day Range
$110.43
$138.23
52-Week Range
$108.35
$160.27
Dividend Yield
0.79%
Waters stock logo

42. Waters NYSE:WAT

$377.42 +9.29 (+2.52%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$377.06 -0.37 (-0.10%)
As of 07/9/2026 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Further, the company provides thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.

Market Capitalization
$36.15 billion
P/E Ratio
47.96
Consensus Rating
Moderate Buy
Consensus Price Target
$403.60 (+6.9% Upside)
Volume
529,790 shares
Average Volume
894,168 shares
Today's Range
$371.23
$381.32
50-Day Range
$291.73
$384.12
52-Week Range
$275.05
$414.15
Dividend Yield
N/A
IQVIA stock logo

43. IQVIA NYSE:IQV

$209.18 +5.39 (+2.64%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$207.81 -1.36 (-0.65%)
As of 04:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. More about IQVIA

Pros of IQVIA

  • The company recently reported earnings per share of $2.90, exceeding analysts' expectations, which indicates strong financial performance and potential for growth.
  • IQVIA Holdings Inc. has experienced an 8.4% increase in revenue compared to the same quarter last year, showcasing its ability to grow in a competitive market.
  • The stock is currently trading at approximately $177, which may be seen as undervalued, especially with the board's recent approval of a $2.00 billion share buyback program, indicating confidence in the company's future.

Cons of IQVIA

  • The company's debt-to-equity ratio is relatively high at 2.20, which may indicate higher financial risk and potential challenges in managing debt levels.
  • Despite recent revenue growth, the stock has seen fluctuations, with a twelve-month high of $247.04 and a low of $154.50, suggesting volatility that could deter risk-averse investors.
  • Analyst ratings are mixed, with some downgrading the stock from "buy" to "hold," which may reflect uncertainty about future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$34.01 billion
P/E Ratio
25.92
Consensus Rating
Moderate Buy
Consensus Price Target
$224.82 (+7.5% Upside)
Volume
1.10 million shares
Average Volume
1.49 million shares
Today's Range
$203.18
$210.09
50-Day Range
$156.42
$209.18
52-Week Range
$154.50
$247.04
Dividend Yield
N/A
Royalty Pharma stock logo

44. Royalty Pharma NASDAQ:RPRX

$57.96 -0.41 (-0.70%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$58.10 +0.14 (+0.24%)
As of 07/9/2026 06:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. More about Royalty Pharma

Pros of Royalty Pharma

  • The current stock price is around $51, which is relatively stable compared to its one-year high of $57.80, indicating potential for growth.
  • Royalty Pharma plc has a strong return on equity of over 29%, suggesting effective management and profitability, which can attract investors looking for solid financial performance.
  • The company reported a net margin of approximately 33.88%, indicating that it retains a significant portion of revenue as profit, which is appealing for income-focused investors.

Cons of Royalty Pharma

  • The company’s revenue for the latest quarter was significantly below analyst estimates, which may raise concerns about future growth and market performance.
  • With a price-to-earnings ratio of approximately 39.30, the stock may be considered overvalued compared to its earnings, which could deter value-focused investors.
  • The debt-to-equity ratio stands at 0.86, indicating a relatively high level of debt, which could pose risks in times of economic downturns or rising interest rates.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.61 billion
P/E Ratio
39.43
Consensus Rating
Buy
Consensus Price Target
$53.71 (-7.3% Downside)
Volume
3.27 million shares
Average Volume
3.27 million shares
Today's Range
$57.78
$58.84
50-Day Range
$49.49
$58.37
52-Week Range
$34.08
$58.84
Dividend Yield
1.61%
Centene stock logo

45. Centene NYSE:CNC

$67.47 +0.39 (+0.57%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$67.02 -0.45 (-0.67%)
As of 04:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. More about Centene

Pros of Centene

  • Centene Co. recently reported earnings per share (EPS) of $3.37, significantly exceeding analyst expectations, indicating strong financial performance and potential for future growth.
  • The company achieved a revenue of approximately $49.94 billion for the latest quarter, surpassing estimates, which reflects robust demand for its healthcare services.
  • Analysts have a generally positive outlook on Centene Co., with several upgrades to target prices, suggesting confidence in the company's future performance.

Cons of Centene

  • Despite strong revenue growth, Centene Co. has a negative net margin of 3.25%, which may raise concerns about profitability and cost management.
  • The stock has a price-to-earnings (P/E) ratio of -4.82, indicating that the company is currently not profitable based on traditional earnings metrics, which could deter risk-averse investors.
  • There are mixed ratings from analysts, with some issuing "Hold" and "Sell" ratings, suggesting uncertainty about the stock's future performance.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$33.13 billion
P/E Ratio
N/A
Consensus Rating
Hold
Consensus Price Target
$62.50 (-7.4% Downside)
Volume
4.57 million shares
Average Volume
5.06 million shares
Today's Range
$66.12
$67.87
50-Day Range
$52.98
$68.34
52-Week Range
$25.08
$69.29
Dividend Yield
N/A
BeOne Medicines stock logo

46. BeOne Medicines NASDAQ:ONC

$302.83 +0.95 (+0.31%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$302.87 +0.04 (+0.01%)
As of 04:06 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Market Capitalization
$33.12 billion
P/E Ratio
67.75
Consensus Rating
Moderate Buy
Consensus Price Target
$391.38 (+29.2% Upside)
Volume
134,160 shares
Average Volume
289,022 shares
Today's Range
$300.50
$306.59
50-Day Range
$260.27
$317.00
52-Week Range
$249.00
$385.22
Dividend Yield
N/A
Alcon stock logo

47. Alcon NYSE:ALC

$67.07 +0.51 (+0.76%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$67.12 +0.05 (+0.08%)
As of 04:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alcon Inc researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. More about Alcon

Pros of Alcon

  • The current stock price is around $87.48, which reflects a stable valuation in the market.
  • Alcon Inc. has shown a month-to-month increase in shares shorted, indicating growing investor interest and potential for upward price movement.
  • The company maintains a significant institutional ownership percentage, suggesting confidence from large investors in its long-term prospects.

Cons of Alcon

  • The fifty-two week performance shows a decline of about 7.53%, which may raise concerns about the company's recent financial health and market position.
  • Despite a recent increase in shares shorted, the overall short interest remains relatively low, which could indicate a lack of strong bullish sentiment among investors.
  • The days to cover is around 4.2, suggesting that it may take some time for short sellers to cover their positions, which could lead to volatility in the stock price.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$32.92 billion
P/E Ratio
40.40
Consensus Rating
Moderate Buy
Consensus Price Target
$85.12 (+26.9% Upside)
Volume
1.41 million shares
Average Volume
1.83 million shares
Today's Range
$66.33
$67.18
50-Day Range
$61.98
$74.86
52-Week Range
$61.83
$92.55
Dividend Yield
N/A
Zoetis stock logo

48. Zoetis NYSE:ZTS

$75.06 -0.04 (-0.05%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$75.33 +0.27 (+0.36%)
As of 04:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. More about Zoetis

Pros of Zoetis

  • The current stock price is around $84, which may present a buying opportunity for investors looking for growth in the animal health sector.
  • Zoetis Inc. has demonstrated strong financial performance with a net margin of 27.80%, indicating effective cost management and profitability.
  • The company has a robust return on equity of 66.85%, suggesting that it efficiently generates profits from shareholders' investments.

Cons of Zoetis

  • The company recently reported earnings of $1.53 per share, missing analysts' expectations, which may raise concerns about its growth trajectory.
  • Zoetis Inc. has a relatively high debt-to-equity ratio of 2.80, indicating that it relies heavily on debt financing, which could pose risks in a rising interest rate environment.
  • Despite a year-over-year revenue increase of 2.9%, the revenue for the latest quarter fell short of analyst estimates, suggesting potential challenges in meeting growth targets.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$31.48 billion
P/E Ratio
12.45
Consensus Rating
Hold
Consensus Price Target
$123.46 (+64.5% Upside)
Volume
5.05 million shares
Average Volume
6.49 million shares
Today's Range
$74.01
$75.86
50-Day Range
$71.88
$115.10
52-Week Range
$71.47
$161.77
Dividend Yield
2.82%
Veeva Systems stock logo

49. Veeva Systems NYSE:VEEV

$189.82 +1.65 (+0.87%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$190.10 +0.29 (+0.15%)
As of 04:30 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Veeva Systems Inc provides cloud-based software for the life sciences industry. It offers Veeva Commercial Cloud, a suite of software and analytics solutions, such as Veeva customer relationship management (CRM) that enable customer-facing employees at pharmaceutical and biotechnology companies; Veeva Vault PromoMats, an end-to-end content and digital asset management solution; Veeva Vault Medical that provides source of medical content across multiple channels and geographies; Veeva Crossix, an analytics platform for pharmaceutical brands; Veeva OpenData, a customer reference data solution; Veeva Link, a data application that allows link to generate real-time intelligence; and Veeva Compass includes de-identified and longitudinal patient data for the United States. More about Veeva Systems

Pros of Veeva Systems

  • The company reported strong earnings per share of $2.24 for the latest quarter, exceeding analysts' expectations, which indicates robust financial performance.
  • Veeva Systems Inc. achieved a revenue of approximately $882.95 million during the quarter, reflecting a significant year-over-year growth of 16.3%, showcasing its expanding market presence.
  • With a net margin of 28.37%, Veeva Systems Inc. demonstrates effective cost management and profitability, which can be attractive to investors looking for financially healthy companies.

Cons of Veeva Systems

  • Despite strong earnings, the stock may face volatility due to market fluctuations and investor sentiment, which can impact short-term performance.
  • The company operates in a highly competitive sector, which could pressure margins and growth rates as new entrants and technologies emerge.
  • Veeva Systems Inc. has a return on equity of 13.72%, which, while positive, may be lower compared to some industry peers, potentially indicating less efficient use of equity capital.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$30.57 billion
P/E Ratio
33.84
Consensus Rating
Moderate Buy
Consensus Price Target
$250.96 (+32.2% Upside)
Volume
1.28 million shares
Average Volume
2.44 million shares
Today's Range
$182.09
$190.09
50-Day Range
$153.20
$192.40
52-Week Range
$148.05
$310.50
Dividend Yield
N/A
ResMed stock logo

50. ResMed NYSE:RMD

$208.64 +2.80 (+1.36%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$207.25 -1.39 (-0.67%)
As of 07/9/2026 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. More about ResMed

Pros of ResMed

  • The company reported a strong earnings per share (EPS) of $2.86 for the latest quarter, exceeding analyst expectations, which indicates robust financial performance.
  • ResMed Inc. has demonstrated a significant year-over-year revenue growth of approximately 10.8%, showcasing its ability to expand its market presence and increase sales.
  • The current stock price is around $180, reflecting investor confidence and market interest in the company's growth potential.

Cons of ResMed

  • The dividend yield is relatively low at around 1.3%, which may not be appealing for income-focused investors seeking higher returns from dividends.
  • Despite recent growth, the competitive landscape in the medical device sector is intense, which could impact ResMed Inc.'s market share and pricing power.
  • The company's dividend payout ratio is 23.14%, indicating that a significant portion of earnings is retained for reinvestment, which may limit immediate returns for shareholders.
A.I. GeneratedThese insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms.
Market Capitalization
$29.86 billion
P/E Ratio
20.12
Consensus Rating
Moderate Buy
Consensus Price Target
$266.55 (+27.8% Upside)
Volume
1.48 million shares
Average Volume
1.55 million shares
Today's Range
$205.00
$209.33
50-Day Range
$183.01
$219.62
52-Week Range
$180.26
$293.81
Dividend Yield
1.17%